An observational study in Central Serous Chorioretinopathy (CSC), sponsored by Sun Yat-sen University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-16.
Sponsored by Sun Yat-sen University · Observational
By leveraging parameters including fractal dimension and topological index, we constructed a quantitative evaluation framework for ultra-widefield optical coherence tomography angiography (UWF-OCTA) images in patients with central serous chorioretinopathy (CSC), thus overcoming the limitations of conventional qualitative analysis.
Central serous chorioretinopathy (CSC) is a macular disorder characterized by choroidal hyperpermeability and serous retinal detachment, with chronicity leading to irreversible visual impairment. Optical coherence tomography angiography (OCTA) allows non-invasive, high-resolution 3D imaging of choroidal microcirculation, but traditional OCTA analysis relies on qualitative assessment, which cannot quantify vascular structural heterogeneity.
This prospective cohort study will enroll 120 subjects, including CSC patients and healthy controls, who will be allocated to acute, chronic, recurrent CSC groups, or healthy control group. Ultra-widefield swept-source OCTA (UWF SS-OCTA) will be used to capture choroidal vascular images. Geometric parameters (fractal dimension, topological index, 3D vascular diameter) will quantify vascular complexity, distribution, and morphology. Strict inclusion/exclusion criteria and matching for age, gender, and refraction will ensure baseline comparability. Follow-up visits will be conducted at 1, 3, 6, and 12 months post-treatment, with repeated OCTA to evaluate dynamic changes in geometric parameters and their associations with treatment response.
This study innovatively integrates geometric methods with UWF-OCTA to establish a quantitative choroidal vascular evaluation framework for CSC. It aims to identify stage-specific vascular characteristics, explore correlations between geometric markers (e.g., dynamic fractal dimension changes) and the efficacy of laser photocoagulation/anti-VEGF therapy, and validate these markers as non-invasive prognostic indicators. UWF-OCTA will enable comprehensive detection of vascular abnormalities, providing evidence for precise CSC management.
84 studies on the registry are indexed under Central Serous Chorioretinopathy; 14 are open to participants now.
This study's planned enrollment of 120 is close to the median of 120 across 21 observational studies indexed under Central Serous Chorioretinopathy.
Browse Central Serous Chorioretinopathy studies →Sun Yat-sen University is the lead sponsor of 1,690 studies on the registry; 619 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study subjects were recruited from outpatients of the Medical Retina Department at Zhongshan Ophthalmic Center, and eligible cases meeting the study criteria were selected from the outpatient medical record system.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-Presence of other ophthalmic diseases that may affect retinal or choroidal imaging or analysis, including but not limited to: Significant refractive media opacities interfering with OCTA imaging (e.g., severe cataract, vitreous hemorrhage);
Uncontrolled diabetes mellitus; Uncontrolled hypertension; Active uncontrolled infection; (COPD) with dyspnea at rest;
Spherical equivalent (SE) \< -6.0 diopters or > +3.0 diopters, or Axial length (AL) > 26.0 mm;
-Any other condition that, in the opinion of the investigator, would make participation unsafe or interfere with protocol adherence.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically, serous retinal detachment (SRD) can be detected via fundus examination and optical coherence tomography (OCT), along with focal or multifocal retinal pigment epithelium (RPE) changes confined to small pigment epithelial detachment (PED) lesions. Fundus fluorescein angiography (FFA) demonstrates RPE leakage. SRD typically resolves within 3-4 months, and in most cases, no long-term symptoms persist except for color discrimination deficits in some patients.
When the disease course exceeds 4-6 months, obvious multifocal atrophic retinal pigment epithelium (RPE) changes, multifocal leakage, and extensive RPE atrophy can be observed. Fundus autofluorescence (FAF) shows hypofluorescence in the RPE-damaged areas.
The patient has a history of one or more previous episodes, during which the symptoms completely resolved or significantly improved, and optical coherence tomography (OCT) examination showed complete absorption of subretinal fluid, with reattachment of the neurosensory retina. After complete remission of the first (or previous) episode (an interval of at least 3-6 months is generally considered), the patient develops typical symptoms of central serous chorioretinopathy (CSC) again, accompanied by objective evidence of the acute or chronic phase, such as changes detected by OCT or fundus fluorescein angiography (FFA).
Healthy control subjects without any local or systemic diseases
Choroidal Vascular Fractal Dimension
Choroidal vascular fractal dimension quantified from optical coherence tomography angiography (OCTA) images.
Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months
Maximum subretinal fluid height
The maximum height of subretinal fluid measured in micrometers (μm) on optical coherence tomography angiography (OCTA) images.
Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months
Subretinal fluid area
The basal area of subretinal fluid measured in square millimeters (mm²) on optical coherence tomography angiography (OCTA) images.
Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months
Subretinal fluid volume
The volume of subretinal fluid measured in cubic millimeters (mm³) on optical coherence tomography angiography (OCTA) images.
Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months
Choroidal vascular branching index
The branching index of choroidal blood vessels quantified from optical coherence tomography angiography (OCTA) images.
Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months
Choroidal Vascular Connectivity Index
The connectivity index of choroidal blood vessels quantified from optical coherence tomography angiography (OCTA) images.
Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months
Mean curvature of choroidal blood vessels
The mean curvature of choroidal blood vessels quantified from optical coherence tomography angiography (OCTA) images.
Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months
Mean curvature of retinal blood vessels
The mean curvature of retinal blood vessels quantified from optical coherence tomography angiography (OCTA) images.
Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Dec 2025; primary completion for Jun 2027, 18 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Serous Chorioretinopathy →